Clinical trials — Lanton Law Blog

Rising API Tariffs Are Forcing Pharma to Shift R&D Resources

In Part 3 of our interview; Lanton Law speaks with Applied Clinical Trials on the highlights of how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines.

FDA, healthcare, life sciences, pharmaceuticals, PhRMARon LantonJune 16, 2025pharmaceutical tariffs, tariffs, active pharmaceutical ingredients, R&D, FDA, Clinical trials

Lanton Law Talks to Applied Clinical Trials About How FDA Cuts Are Creating New Bottlenecks in Clinical Operations

In Part 2 of the interview; Ron Lanton, partner, Lanton Law, talks FDA layoffs and their impact on inspections and clinical trial timelines. The interview can be seen here.

clinical research, clinical trials, FDA, healthcare, HHSRon LantonJune 7, 2025Clinical trials, FDA, R&D, inspections, supply chain

Lanton Law Talks to Applied Clinical Trials About The Hidden Impact of Drug Pricing on Government Clinical Trials

In part one of this video interview, Ron Lanton III, Esq., partner, Lanton Law, discusses how a potential increase in drug costs could affect the clinical research industry.

clinical research, clinical trials, HHS, healthcareRon LantonJune 7, 2025Clinical trials, drug prices, rebates, HHS, government sponsored clinical trials

FDA Releases Draft Guidance To Encourage Enhancing Clinical Trial Diversity

The FDA has just released draft guidance in the Biden Administration’s effort to encourage the industry to enhance clinical trial diversity.

clinical research, FDA, healthcare, life sciencesRon LantonApril 28, 2022clinical trial diversity, Clinical trials, FDA

What to Know about CURES 2.0

In November 2021, U.S. Reps. Fred Upton (R-MI) and Diana DeGette (D-CO) today introduced their bipartisan Cures 2.0 legislation. The bill which is aimed at helping patients of innovative companies within healthcare and life sciences can be viewed here.

Biosimilars, biologics, Congress, health system, healthcare, HealthIT, HHS, life sciencesRon LantonMarch 28, 2022CURES 2.0, 21st Century CURES Act, cancer, diabetes, ALS, Alzheimer’s, Advanced Research Projects Agency for Health, Clinical trials, CRO, laboratory